Document

Government Owned Invention Available for License: Quantitative Particle Identification (QPID) Digital Autoradiography System

The National Cancer Institute (NCI) seeks research co- development partners and/or licensees for a QPID digital autoradiography system with particle identification capabilities.

Department of Health and Human Services
National Institutes of Health

AGENCY:

National Institutes of Health, HHS.

ACTION:

Notice.

SUMMARY:

The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a QPID digital autoradiography system with particle identification capabilities.

FOR FURTHER INFORMATION CONTACT:

Inquiries related to this license opportunity should be directed to: Eric Cheng, Ph.D., Technology Transfer Manager, NCI, Technology Transfer Center, Email: or Phone: 240-276-5978.

SUPPLEMENTARY INFORMATION:

Autoradiography is a photographic process that exposes a medium, sensitive to radiation, to a sample emitting radiation. The current state of the art involves exposing a thin slice of tissue to an ionization-sensitive film for several hours or days and then scanning the film into an autoradiography image. This image is created using the sum of the ionizations from all the decays that occurred during the time of exposure on the ionization-sensitive medium. Imaging quality of these samples can be improved by collecting information from each individual decay to enhance the autoradiographic measurement.

Researchers at NCI developed a QPID digital autoradiography system to measure the energy deposition from charged particles for each individual radioactive decay. The QPID leverages the ionizing radiation detection features of the Timepix3 detector to generate autoradiograph images in units of dose per unit time and area. The high readout speed of the Timepix3 gives the detector the capability to measure separate decay ionizations. It also segregates the image into one generated only by alpha and the other only by beta particles. A gamma detector was interfaced with the Timepix3—allowing tagging charged particle ionization events in coincidence with a gamma emission during the isotope decay. This allows for a method to distinguish between alpha and positron emitting radioisotopes when imaged concurrently in the same pathology sample. This is the most unique feature of the QPID which will aid the development of new theranostic treatments in which two similar ligands are used.

“This Notice is in accordance with 37 CFR 404.4 Authority to grant licenses.”

NIH Reference Number: E-201-2023.

Related Technologies: N/A.

Product Type: Device.

Therapeutic Area(s): Oncology | Radiology.

Development Stage: Prototype.

Publications:

Patens: PCT Stage, filed May 29 2025.

Potential Commercial Applications:

Competitive Advantages:

Collaboration Opportunity: Researchers at the NCI seek licensing and/or co-development research collaborations for developing the QPID system for improved autoradiography imaging.

( printed page 52066)

Dated: August 7, 2026.

Richard U. Rodriguez,

Associate Director, Technology Transfer Center, National Cancer Institute.

[FR Doc. 2026-16439 Filed 8-11-26; 8:45 am]

BILLING CODE 4167-05-P

Legal Citation

Federal Register Citation

Use this for formal legal and research references to the published document.

91 FR 52065

Web Citation

Suggested Web Citation

Use this when citing the archival web version of the document.

“Government Owned Invention Available for License: Quantitative Particle Identification (QPID) Digital Autoradiography System,” thefederalregister.org (August 12, 2026), https://thefederalregister.org/documents/2026-16439/government-owned-invention-available-for-license-quantitative-particle-identification-qpid-digital-autoradiography-syste.